Concepedia

Publication | Closed Access

Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells

DOI

10

Citations

11

References

2022

Year

M. Opdam, J H de Leijer, Nathan den Broeder, Rogier M. Thurlings, W. van der Weele, Michael T. Nurmohamed, Marc R. Kok, Lenny van Bon, David F Ten Cate, Lise M Verhoef,
Lara D. Veeken

Abstract

These secondary analyses of the REDO trial confirmed the observed dose-dependent infection risk. Additionally, we found that infection risks were higher shortly after RTX infusion. However, a mediating pathway was not found.

References

YearCitations

Page 1